New hope for advanced cervical cancer: experimental drug SHR-A2102 enters phase 3 trial
NCT ID NCT07418749
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing a new drug called SHR-A2102 against standard chemotherapy in 398 people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and PD-(L)1 inhibitors. The main goal is to see if SHR-A2102 helps people live longer. Participants are randomly assigned to receive either the new drug or one of several standard chemotherapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A2102
What this could lead to
If successful, this could offer a new treatment option for people with advanced cervical cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than existing chemotherapies and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact